Alluvi, known as BI 4744, presents a promising advance in obesity treatment. This dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates compelling results in https://alluvi-healthcare660149.wikifiltraciones.com/user